Figure 5

NK cell populations in the TSLN are increased by Ad5IL-12 vector treatment. TRAMP-C1 tumors in C57BL6 mice were treated with injection of PBS, DL70-3, or the Ad5IL-12 vector. Another set of mice corresponding to each of these treatment groups received an additional daily administration of RU486 IP for 1 week. At the end of treatment, TSLN were isolated and analyzed by flow cytometry for their content of Ly49C⁺ NK cells. A representative dot plot is shown from one set of animals out of 3 separate experiments. Cumulative data from 3 flow cytometry analyses demonstrated Ly49C expression percentages averaged 7.95 ± 2.8 for PBS, 8.86 ± 2.7 for RU486, 11.94 ± 6.0 for DL70-3, 12.07 ± 4.7 for DL70-3 + RU486, 19.88 ± 9.9 for Ad5IL-12 and 21.33 ± 9.5 for Ad5IL-12 + RU486 treatment groups; n = 6. TSLN lymphocytes from two treated animals from each treatment were analyzed in each flow cytometry experiment.